



Dheise Oliveira's

**EARLY
INVESTOR
ALERT**

Late Fall 2017

**"I'VE NEVER SEEN A BETTER
OPPORTUNITY THAN VILACTO
BIO (OTC:VIBI)!"**

INVESTOR ALERT: Big Pharma Is Dying. And There's Just One Stock You Need To Survive The Collapse...

Big Trouble For Big Pharma

Read On To Discover The Tiny Company Whose Patents Could Make "Old School" Pharmaceuticals Obsolete!

**YOUR \$5,000 INVESTMENT IN
VILACTO BIO
(STOCK SYMBOL "VIBI")
COULD TURN INTO \$35,000
WITHIN 10 MONTHS!**

Executive Summary:

This exclusive report summarizes how investors can profit from the revolutionary new cosmetic and pharmaceutical products from **VILACTO BIO (STOCK SYMBOL "VIBI")**

Vilacto Bio is a **fast growing company in the cosmeceutical industry**, a major subsector of the pharmaceutical and cosmetics markets.

The company owns **revolutionary** new skincare products that could transform the way doctors treat skin disorders.

This new technology is **100% patent protected**, giving Vilacto Bio exclusive rights to its development.

Current treatments for skin care and anti-aging are "decades behind the times," while VIBI promises to **totally transform and revolutionize** the market. This could lock Big Pharma out of the cosmeceutical industry and create a "cottage industry" that only VIBI investors will profit from.



READ ON FOR THE FULL STORY ON 2017'S "UNDER-THE-RAD" STOCK ABOUT TO EXPLODE!

Dear Investor,

My name is Dheise Oliveira, and I've been in the beauty industry all my life. I have never seen a better opportunity than this. Ever!

Get ready for the biggest pharmaceutical profit bonanza in decades.

Your **\$5,000** could return thousands of dollars in profit... even up **to \$35,000!**



As you're about to discover, one company's revolutionary new technology could transform the cosmeceutical sector of the pharma industry... *forever*.

The company has spent years developing patented anti-aging treatments...

...And because of this **patent** protection, the company and its investors will reap the profits from the sales.

This new product is the outcome of years of research by some of the world's top doctors and pharmacists. The company has enlisted the help of researchers from leading universities to develop an anti-inflammatory drug that may reverse aging, while boosting immune functioning and helping people live better lives.

The potential of this new technology is almost unlimited. Based on some of the most advanced research in pharmaceuticals and skin conditions, it has shown promise in treating wrinkles and other aging symptoms.

But this is not just one product.

It's a *patented ingredient* that the company plans to use in dozens of different skincare product lines. A combination of rare biological compounds that has never before been released to the market.

The potential gains to investors are enormous.

It's possible that a \$5,000 investment in this stock could lead to profits upward of \$35,000 within just 10 months.

JUST LOOK AT THE GAINS THESE OTHER TOP PHARMACEUTICAL AND COSMETIC STOCKS ARE SEEING



For comparison, the S&P 500 returned 9.5% in the same period while the Dow Jones Index returned 13.5%. This sector is totally outperforming the market by leaps and bounds, and that could mean serious returns for smart investors who get in early.

In fact...

...This is one of the few topical skincare companies with planned clinical trials. In an industry that's dominated by untested herbal and 'natural remedies', Vilacto Bio (OTD:VIBI) is putting its money where its mouth is with **real medical research**. If successful, these trials could pave the way for a "revolution" in skincare that generates a windfall of profits for early investors.

THIS COULD EASILY BE ONE OF **THE BEST PHARMA** PLAYS FOR INVESTORS LOOKING TO **MAKE A QUICK** **PROFIT!**



This is based on years of stock market analysis and research.

I have made countless stock recommendations over the years, including dozens that have gone on to **deliver 100%+ annual returns.**

There is a very strong chance that **Vilacto Bio** could be the next on the list.

What does that mean for you as an investor?

It's very simple:

VILACTO BIO COULD ADD QUICK GAINS TO YOUR ACCOUNT -- **RESEARCH STOCK SYMBOL VIBI TODAY!**



It's all thanks to a Patented compound called Lactoactive[®], the product of years of research and development by leading scientists.

So what is Lactoactive[®], and why should you care?

Basically it's a nanoparticle composition of refined bovine colostrum that has proven extremely effective in treating a number of skin conditions.

The science behind it is complex. To put it simply, it makes human body cells healthier by keeping dangerous invasive compounds out.

Why is Big Pharma so scared of this?



It helps to understand how they make money. The pharmaceutical industry is a huge profit center that profits by charging obscene amounts for highly risky treatments that don't necessarily work.

Think of things like...

Botox

Microdermabrasion

Facelifts

They cost an arm and a leg, come with huge risks, and aren't guaranteed effective. Think of all the 'before and after' pictures that circulate the tabloids whenever a celebrity has a procedure go wrong. Then think of the potential value of a **100% safe, patented solution that makes these risky procedures unnecessary.**

Vilacto Bio may deliver just that with a line of anti-aging products based on Lactoactive®. Preliminary research has shown that the compound has an anti-inflammatory effect that strengthens the skin, and fights against cell damage. But perhaps even more important is the compound's anti-aging properties, which could totally transform the way the elderly population receives medical treatment.

CONSIDER

VILACTO BIO
(STOCK SYMBOL: VIBI)

RIGHT NOW!

The Cosmeceutical Market: The "Silent Juggernaut" That's **Making Investors Rich**

Most investors have never heard of the "cosmeceutical industry." It has flown under the radar with relatively little media coverage or hype.

But for Wall Street Fat cats and people in the know, it's a **well known profit center.**

Companies like Estee Lauder, Align Technology and Revance therapeutics are seeing gains that far exceed the market averages.

But what makes **Vilacto Bio** different is that it's NOT just a cosmetics company with a few medical-grade products.

It's a cosmeceutical company that exclusively develops patented, pharmaceutical products that could transform the anti-aging market.

The potential gains--for the company AND savvy investors who get in early--are enormous.

Just look at these facts that prove the massive profit potential in this industry:

The global cosmetics market, including both 'cosmeceuticals' and standard non-medical products, has a **total size of \$382 billion.**

The cosmeceutical segment of the market is expected to reach **\$61 billion by 2020.**

The worldwide population of 'aging' people is currently 600 million, and that grows by 3.2% per year. That's three times the growth of the general population, which means the target market for anti-aging products is **growing daily.**

68% of Gen-Xers use anti-aging products every day, while 20% more use them at least once a week.

There is one dermatologist for every 30,000 people in the United States. In other words, there's a **huge shortage**, and most people just can't get the skin care they need. So there's a **huge opportunity** to 'bridge the gap' by providing efficient skin treatments that require no specialist attention.

In short? There is a massive market for cosmeceutical products, and companies like **VIBI stand to reap the vast majority of the profit.**



Why This Could Spell **"The End"** For Big Pharma

Vilacto Bio's treatments are cheaper, more accessible and less dangerous than the solutions peddled by big pharma.

When it comes to anti-aging, big pharma mostly specializes in treatments that require surgical intervention.

By contrast, Vilacto Bio creates affordable topical creams that can be used for a wide variety of conditions. Its planned products are all based on its patented ingredient, Lactoactive[®], and include:

Skin cream

Skin lotion

Skin gel

Lip Balm

Tattooed Skin Gel

Baby Skin Gel

Maternal Skin Cream

Foot Cream

Heel Cream

Antiperspirant Foot Cream



Vilacto Bio's products have the potential to cut into Big Pharma's profits dramatically.

More importantly, as more and more stores and pharmacies stock them, they could generate millions in profits for VIBI and its investors.

It might yet become the **#1 Penny Stock of 2017!**

5 REASONS TO GET SOME
VILACTO BIO
(STOCK SYMBOL: VIBI)
ONTO YOUR RADAR RIGHT NOW

Reason 1: Rock Solid Patent Protection

Vilacto Bio's main ingredient, Lactoactive[®], has been **patented and proven effective** for a number of conditions. It can cure skin disorders, reverse the aging process, and even improve the functioning of the immune system.

To quote the company's website:



"Using the patented ingredient Lactoactive[®], Vilact[®] is making waves in the skin care industry with their innovative treatment. Using the therapeutic proteins found in their products, they're able to regenerate skin on the cellular level and fight aging at its core"

In plain English, Vilacto Bio's products fight aging at its source.

But not only are Vilacto Bio's products extremely effective, they're also covered by patents. This means the company will have the **exclusive right** to manufacture and sell them for years to come. For investors, this is practically like being able to "print money."

Reason 2: Huge Market Demand

There is a **massive** yet largely unmet market demand for cosmeceutical products.

To understand why, it pays to look at demographics.

The global population is aging rapidly. There are an estimated 600 million aging people in the world. That number is growing by 3.2% annually, more than 3 times

the growth in the younger population.



With an aging population comes more demand for anti-aging remedies.

But current anti-aging solutions, like Botox, Facelifts and Microdermabrasion, tend to be expensive and risky. Generally, they involve going to a surgeon, spending thousands on procedures that aren't covered by insurance, and risking disfigurement in the process.

What's the alternative?

Currently, not much. Customers may turn to natural treatments and herbal remedies, but most of these don't work.


Patients are *screaming* for an **effective** topical anti-aging remedy without the dangers of surgery. And Vilacto Bio is perfectly positioned to be the company that delivers that solution.

Reason 3: Red-Hot Market Sector

The cosmeceutical industry is on fire right now.

Research indicates that it will grow by around 9% per year between 2017 and 2022. That's impressive enough growth as it is. But there's reason to believe that this sector could grow even faster than current projections suggest.

Currently, 68% of Gen-Xers use anti-aging products daily. And as the number of individuals in that age bracket grows, so will the demand for anti-aging products.



Cosmeceuticals is a market at the intersection of cosmetics and pharmaceuticals. The **total** cosmetic market size is **\$382 billion**, while cosmeceuticals make up around \$60 billion of that. By delivering cosmeceutical products that really work, **Vilacto Bio** can claim a huge slice of the \$382 billion cosmetics market, potentially becoming a leading player in the space.

And the returns for **VIBI** investors will be significant. Some say this stock could double or triple in value this year--and that would add a serious wollop of gains to your portfolio.

Reason 4: Diverse Product Line

Another huge advantage that **VIBI** has is a large and diverse product line.

Put simply, the company is planning on making "something for everyone" in the anti-aging market:



Skin cream
Skin lotion
Skin gel
Lip Balm
Tattooed Skin Gel
Baby Skin Gel
Maternal Skin Cream
Foot Cream
Heel Cream
Antiperspirant Foot Cream
And more

All of these products will be based on the same active ingredient, Lactoactive[®], a patented anti-inflammatory agent with anti-aging properties. But by marketing this ingredient in several formulations, **Vilacto Bio** will target several market segments and maximize its **profit potential**.

Reason 5: Potential For Buyout At High Valuation

Last but not least, VIBI is **sitting on top** of a MOUNTAIN of intellectual property that big pharma would love to get its hand on.

Lactoactive® is a **revolutionary** product. It has the potential to make botox, skin creams, and other anti-aging therapies obsolete. Once big pharma hears about this, it may initiate a **panic-fueled bidding war to buy out VIBI for a premium valuation.**

Not only does **VIBI** hold all the patents already mentioned, it also holds a number of related patents for other compounds. What does that mean? That big pharma cannot simply "copycat" Lactoactive® by making similar products of its own.

So there could be two options:

VIBI corners the market on Lactoactive® products and swallows up all the profit.

One of the pharma giants buys out VIBI entirely, possibly at a premium price that will enrich the company's investors.

Either way, the situation is a **complete win-win** for VIBI investors.

WHAT TO DO ABOUT IT?
**CONSIDER SOME VIBI FOR
YOUR PORTFOLIO**

This newsletter has been covering the markets for years. It has featured some of the **best performing stocks** of the past decade, years before Wall Street caught wind of them.

There has never been a stock like **VIBI**.

This is a company that...

Has exclusive rights to a **PATENTED** ingredient that could "reverse" the aging process.

Is backed by a team of **leading scientific researchers** who are working on new patents every day.

Has plans to include this patented ingredient in **10 different products, ranging from skin cream to lip balm and beyond.**

Has even further plans to roll out **MORE** products, including Leganze[®], a totally new cosmeceutical product with a wide range of **potential** therapeutic uses.

The global cosmetics industry is worth \$382 **billion**, while cosmeceuticals make up \$60 billion of that.

By releasing a product that can **totally revolutionize** skincare, **VIBI** could swallow up a huge percentage of both of these markets.


At the time of this writing, VIBI stock sells for **dirt cheap**.

How high could it go?

The sky is the limit.

Even if the company reached a \$1 billion valuation (just 1/60th the size of the cosmeceutical industry), investors could pocket a massive gain of **1539%**.

But don't sit by the sidelines and wait.



Take Action And Get Some Vilacto Bio (stock symbol "VIBI") Stock In Your Portfolio NOW, While It's Still Cheap!

CONSIDER
VILACTO BIO
(STOCK SYMBOL: VIBI)
RIGHT NOW!

P.S. The global population is aging at a rapid rate and the demand for anti-aging products is EXPLODING. Vilact[®] and Lactoactive[®] are among the only PROVEN anti-aging solutions to meet the insatiable demand that's only set to grow from here. Just one of many reasons to get some VIBI in your portfolio today.

P.P.S. VIBI owns the exclusive trademark rights to Lactoactive[®] and has many other intellectual property rights. This is the only company that can sell Lactoactive[®] which means it virtually "has the market cornered" with no direct competition in the near future.

Disclaimer: Information about many publicly traded companies, including Vilacto Bio Inc. and other investor resources can be found directly from the Securities and Exchange Commission as well as from its website, www.sec.gov. It is recommended that any investment in any security should be made only after consulting with your registered investment advisor and only after reviewing all publicly available information, including the statements of the company. Do not base any investment decisions upon any material found in this advertisement. The information contained herein has been prepared for informational purposes only and is not intended in any way to be used as a complete source of information on any particular company, including Vilacto Bio Inc. This publication does not purport to provide a full analysis of any company's financial position. Any public company's financial position and all other information regarding the company should be verified directly with the company and its regulatory disclosures. Dheise Oliveira has been paid \$4,000 to be a spokesperson in this advertisement. An individual should not invest in the securities of Vilacto Bio Inc. based solely on information contained in this advertisement. Investing in securities is speculative and carries significant risk, including the total loss of principal. This advertisement is not intended to be, nor should it be construed as, an offer to buy or sell nor a solicitation to buy or sell securities, nor should it be construed as the provision of any investment related advice nor services tailored to any particular individual's financial situation or investment objective(s). The publisher distributes general content offering impersonalized entertainment to readers and/or prospective readers and is not an investment advisor or broker-dealer registered with either the U.S Securities and Exchange Commission nor with any state securities regulatory authorities. The publisher is neither licensed nor qualified to provide financial advice. As such, the publisher rely upon the "publisher's exclusion" as provided under Section 202(a)(11) of the Investment Advisors Act of 1940 and its corresponding state securities laws. Do not invest in this company unless you can afford to possibly lose your entire investment. The company featured herein appears as paid advertising, paid by a third party to provide public awareness for Vilacto Bio Inc. The publisher understands that in an effort to enhance public awareness of Vilacto Bio Inc. and its securities through the distribution of this online advertisement, if successful, the advertisement will increase investor and market awareness, which could result in increased numbers of shareholders owning and trading the common stock of Vilacto Bio Inc., and/or increase trading volumes, and/or possibly increased share price of the common stock of Vilacto Bio Inc. The publisher and marketing vendors will be managing a total budget of two million dollars, provided for all online advertising and marketing efforts; and will retain any amounts over and above the cost of production, advertising, copywriting services, mailing and other distribution expenses, as a fee for their services. The publisher has not undertaken to determine if paying parties are, or intend to be, directly or indirectly, a shareholder of Vilacto Bio Inc. This publication is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable; nevertheless, the publisher cannot guarantee the accuracy or completeness of the information. The information contained herein contain forward-looking information within the meaning of section 27a of the Securities Act and section 21e of the Securities Exchange Act including statements regarding expected growth of Vilacto Bio Inc. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, the publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results of operations. Factors that could cause actual results to differ include, but are not limited to, the size and growth of the market for the company's products and services, the company's ability to fund its capital requirements in the near and long term, pricing pressures and other risks detailed in the company's filed reports with SEC. To the fullest extent of the law, we will not be liable to any person or entity for the accuracy, quality, completeness, reliability, or timeliness of the information provided herein, nor for any direct, indirect, consequential, incidental special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).